Herbrecht (voriconazole)
Voriconazole versus Amphotericin B for Invasive Aspergillosis
Patient / Population Intervention / Exposure Comparison Outcome
In 277 patients with definite or probable invasive aspergillosis, voriconazole improved successful response and 12-week survival compared with amphotericin B deoxycholate.
N
277
Design
Open-label RCT
Endpoint
Successful response at 12 weeks
Relevance
2
ResultResponse 52.8 % vs 31.6 %; 12-week survival 70.8 % vs 57.9 %.
Herbrecht R, et al. N Engl J Med. 2002;347(6):408-415. 10.1056/NEJMoa020191
Discussion & critique
Established voriconazole as first-line therapy for invasive aspergillosis — isavuconazole later proved a tolerability-equivalent alternative.